<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">21445242</article-id><article-id pub-id-type="pmc">3060800</article-id><article-id pub-id-type="publisher-id">PONE-D-10-02546</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0016988</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Medicine</subject><subj-group><subject>Clinical Research Design</subject><subj-group><subject>Survey Research</subject></subj-group></subj-group><subj-group><subject>Neurology</subject><subj-group><subject>Cerebrovascular Diseases</subject><subj-group><subject>Ischemic Stroke</subject><subject>Hemorrhagic Stroke</subject></subj-group></subj-group><subj-group><subject>Neurorehabilitation and Trauma</subject></subj-group></subj-group></subj-group></article-categories><title-group><article-title>Fatigue after Stroke: Baseline Predictors and Influence on Survival. Analysis of Data from UK Patients Recruited in the International Stroke Trial</article-title><alt-title alt-title-type="running-head">Post-Stroke Fatigue in International Stroke Trial</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Mead</surname><given-names>Gillian E.</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref><xref ref-type="corresp" rid="cor1">
<sup>&#x0002a;</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Graham</surname><given-names>Catriona</given-names></name><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Dorman</surname><given-names>Paul</given-names></name><xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Bruins</surname><given-names>Slot Karsten</given-names></name><xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Lewis</surname><given-names>Steff C.</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Dennis</surname><given-names>Martin S.</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Sandercock</surname><given-names>Peter A. G.</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><collab>on behalf of the UK Collaborators of IST</collab></contrib></contrib-group><aff id="aff1">
<label>1</label>
<addr-line>University of Edinburgh, Edinburgh, United Kingdom</addr-line>
</aff><aff id="aff2">
<label>2</label>
<addr-line>Wellcome Trust Clinical Research Facility, University of Edinburgh, Edinburgh, United Kingdom</addr-line>
</aff><aff id="aff3">
<label>3</label>
<addr-line>Department of Neurology, Newcastle Acute Hospitals NHS Foundation Trust, Newcastle-upon-Tyne, United Kingdom</addr-line>
</aff><aff id="aff4">
<label>4</label>
<addr-line>Division of Medicine, Oslo University Hospital-Ullev&#x000e5;l, Oslo, Norway</addr-line>
</aff><contrib-group><contrib contrib-type="editor"><name><surname>Malaga</surname><given-names>German</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1">Universidad Peruana Cayetano Heredia, Peru</aff><author-notes><corresp id="cor1">&#x0002a; E-mail: <email>Gillian.e.mead@ed.ac.uk</email></corresp><fn fn-type="con"><p>Conceived and designed the experiments: GEM KBS PD SCL MSD PAGS. Performed the experiments: KBS PD MSD PAGS. Analyzed the data: CG SCL. Contributed reagents/materials/analysis tools: SCL. Wrote the paper: GEM CG PD SCL MSD KBS PAGS.</p></fn></author-notes><pub-date pub-type="collection"><year>2011</year></pub-date><pub-date pub-type="epub"><day>18</day><month>3</month><year>2011</year></pub-date><volume>6</volume><issue>3</issue><elocation-id>e16988</elocation-id><history><date date-type="received"><day>22</day><month>9</month><year>2010</year></date><date date-type="accepted"><day>18</day><month>1</month><year>2011</year></date></history><permissions><copyright-statement>Mead et al.</copyright-statement><copyright-year>2011</copyright-year><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.</license-p></license></permissions><abstract><sec><title>Background and Purpose</title><p>Little is known about the associations of post-stroke fatigue or its influence on survival. The vitality component of the Short Form 36 (SF-36) is a valid and reliable measure of post-stroke fatigue. We sought to identify associates of post-stroke fatigue and determine whether fatigue predicted survival.</p></sec><sec><title>Methods</title><p>We used SF-36 vitality scores obtained by postal questionnaires from 1080 UK patients randomised in the International Stroke Trial, at a mean of 64 weeks after stroke onset. We used logistic regression to explore factors at randomisation which predicted SF-36 vitality at follow-up, and the relationship between SF-36 vitality and both SF-36 mental health and SF-36 emotional role function at follow-up. We used Cox proportional hazards to explore the influence of SF-36 vitality at follow-up on subsequent survival, using four different statistical models for handling missing data.</p></sec><sec><title>Results</title><p>Female sex, increasing age, lower mental health and lower emotional role function scores were associated with greater degrees of fatigue after stroke (i.e. lower vitality scores) but these factors explained &#x0003c;30&#x00025; of the variance (R<sup>2</sup>) in fatigue. In two models, fatigue at follow-up was associated with shorter subsequent survival.</p></sec><sec><title>Conclusion</title><p>Increasing age, female sex, emotional role function and mental health were associated with increased fatigue at a mean of 64 weeks after stroke onset, but explained less than 30&#x00025; of the variance. Fatigue was associated with reduced subsequent long-term survival in 2/4 models. Further work is needed to identify the biological substrate of fatigue and to clarify its influence on survival.</p></sec></abstract><counts><page-count count="7"/></counts></article-meta></front><body><sec id="s1"><title>Introduction</title><p>Fatigue is common after stroke, with estimates of prevalence ranging from 16&#x00025; <xref rid="pone.0016988-Glader1" ref-type="bibr">[1]</xref> to 70&#x00025; <xref rid="pone.0016988-Leegard1" ref-type="bibr">[2]</xref>. Fatigue is one of the most distressing symptoms after stroke <xref rid="pone.0016988-vander1" ref-type="bibr">[3]</xref>, yet its aetiology remains uncertain. In the general non-stroke population, fatigue is often a symptom of depression. Several cross-sectional studies <xref rid="pone.0016988-Glader1" ref-type="bibr">[1]</xref>, <xref rid="pone.0016988-vander1" ref-type="bibr">[3]</xref>-<xref rid="pone.0016988-Ingles1" ref-type="bibr">[8]</xref> and one longitudinal study <xref rid="pone.0016988-Schepers1" ref-type="bibr">[9]</xref> have sought associations of fatigue after stroke using different generic fatigue scales. Most <xref rid="pone.0016988-Glader1" ref-type="bibr">[1]</xref>, <xref rid="pone.0016988-vander1" ref-type="bibr">[3]</xref>, <xref rid="pone.0016988-ChoiKwan1" ref-type="bibr">[4]</xref>, <xref rid="pone.0016988-Morley1" ref-type="bibr">[6]</xref>, <xref rid="pone.0016988-Schepers1" ref-type="bibr">[9]</xref> but not all <xref rid="pone.0016988-Staub1" ref-type="bibr">[7]</xref>, <xref rid="pone.0016988-Ingles1" ref-type="bibr">[8]</xref> have found associations with depression. One previous study found an association with variability in blood pressure <xref rid="pone.0016988-Harbison1" ref-type="bibr">[10]</xref>. Early studies of fatigue after stroke suggested that it is more common in brain stem lesions <xref rid="pone.0016988-Staub1" ref-type="bibr">[7]</xref>, but other studies have not shown such an association <xref rid="pone.0016988-Glader1" ref-type="bibr">[1]</xref>, <xref rid="pone.0016988-ChoiKwan1" ref-type="bibr">[4]</xref>, <xref rid="pone.0016988-Morley1" ref-type="bibr">[6]</xref>, <xref rid="pone.0016988-Ingles1" ref-type="bibr">[8]</xref>, <xref rid="pone.0016988-Schepers1" ref-type="bibr">[9]</xref>, <xref rid="pone.0016988-Lynch1" ref-type="bibr">[11]</xref>, <xref rid="pone.0016988-Mead1" ref-type="bibr">[12]</xref>. The single previous study that investigated associations between fatigue and survival found that it was independent predictor of shorter survival <xref rid="pone.0016988-Glader1" ref-type="bibr">[1]</xref>.</p><p>All previous studies of fatigue after stroke used generic fatigue scales which had not been tested for validity or reliability in stroke. The vitality domain of the Short-Form 36 (SF-36) has face validity and is reliable after stroke <xref rid="pone.0016988-Mead1" ref-type="bibr">[12]</xref>, and correlates with other fatigue scales <xref rid="pone.0016988-Lynch1" ref-type="bibr">[11]</xref>. Stroke patients fulfilling a case definition for clinically significant fatigue have lower SF-36 vitality scores than those without clinically significant fatigue <xref rid="pone.0016988-Mead1" ref-type="bibr">[12]</xref>.</p><p>The vitality domain in the original version of the SF-36 includes four questions: In the past four weeks: &#x02018;Did you feel full of pep?&#x02019;, &#x02018;Did you have a lot of energy?&#x02019;, &#x02018;Did you feel worn out?&#x02019; and &#x02018;Did you feel tired?&#x02019; Responses to each question are: &#x02018;All of the time&#x02019;, &#x02018;Most of the time&#x02019;, &#x02018;a Good bit of the time&#x02019;, &#x02018;Some of the time&#x02019; &#x02018;A little of the time&#x02019; and &#x02018;None of the time&#x02019; <xref rid="pone.0016988-Ware1" ref-type="bibr">[13]</xref>. After the responses to the individual questions were recorded, a total score for vitality can be calculated according to the SF-36 scoring manual <xref rid="pone.0016988-Ware1" ref-type="bibr">[13]</xref>. The range of possible scores is from 0 to 100, with higher scores indicating higher vitality (i.e. less fatigue).</p><p>Our aims were to determine: a) what factors at stroke onset predicted SF-36 vitality scores <xref rid="pone.0016988-Ware1" ref-type="bibr">[13]</xref> measured a few months later, b) the relationship between SF-36 vitality measured in survivors a few months after stroke and mood (SF-36 mental health domain and emotional role function domain) and c) influence of SF-36 vitality in survivors on subsequent survival.</p></sec><sec sec-type="materials|methods" id="s2"><title>Materials and Methods</title><p>We used data from patients in the International Stroke Trial (IST), recruited by UK Centres, who had participated in a substudy on quality of life after stroke <xref rid="pone.0016988-Dorman1" ref-type="bibr">[14]</xref>-<xref rid="pone.0016988-Anonymous1" ref-type="bibr">[17]</xref>.</p><sec id="s2a"><title>The International Stroke Trial</title><p>The IST was a randomised controlled trial of the effects of aspirin, subcutaneous heparin, both or neither, among 19,435 patients with acute ischaemic stroke, recruited within 48 hours of stroke onset <xref rid="pone.0016988-Anonymous1" ref-type="bibr">[17]</xref>. To receive the patient's randomised treatment allocation, clinicians telephoned a central randomisation service. During this telephone call, after data on age, gender, pathological subtype of stroke, stroke subtype, neurological deficits, blood pressure and cardiac rhythm had been recorded and checked, the system generated the treatment allocation <xref rid="pone.0016988-Anonymous1" ref-type="bibr">[17]</xref>.</p></sec><sec id="s2b"><title>Collection of SF-36 data</title><p>A subset of the patients recruited by the UK centres in the IST trial participated in a study of quality of life after stroke. Surviving patients (n&#x0200a;=&#x0200a;2253) were sent either a SF-36 or EuroQUOL (another scale to measure quality of life) by postal questionnaire <xref rid="pone.0016988-Dorman1" ref-type="bibr">[14]</xref>-<xref rid="pone.0016988-Dorman3" ref-type="bibr">[16]</xref> at a mean of 64 (SD 30) weeks following randomisation. Between 2<sup>nd</sup> March 1993 and 31<sup>st</sup> May 1995, 1400 patients were sent a SF-36, of whom 1080 responded (77&#x00025;) <xref rid="pone.0016988-Dorman1" ref-type="bibr">[14]</xref>-<xref rid="pone.0016988-Dorman3" ref-type="bibr">[16]</xref>. The SF-36 includes the following domains: vitality, physical functioning, physical role function, social functioning, bodily pain, mental health, emotional role functioning and general health <xref rid="pone.0016988-Ware1" ref-type="bibr">[13]</xref>-<xref rid="pone.0016988-Dorman3" ref-type="bibr">[16]</xref>. Each domain, including the mental health and emotional role function domains, includes several questions. We changed the question &#x02018;Did you feel full of pep?&#x02019; to &#x02018;Did you feel full of life?&#x02019; to ensure its cultural relevance <xref rid="pone.0016988-Ware1" ref-type="bibr">[13]</xref>-<xref rid="pone.0016988-Dorman2" ref-type="bibr">[15]</xref>. The responses to the questions allow a total score for each domain to be calculated using the standardised SF-36 scoring manual <xref rid="pone.0016988-Ware1" ref-type="bibr">[13]</xref>. Scores for each domain range from 0-100, with higher scores indicating better health.</p><p>These data allowed us to explore the relationship between SF-36 vitality a few months after stroke, patient characteristics at randomisation and the SF-36 role emotional and SF-36 mental health a few month after stroke.</p></sec><sec id="s2c"><title>Collection of survival data</title><p>All UK patients in IST were &#x02018;flagged&#x02019; at the Office for National Statistics central registry of deaths, enabling us to collect data on all deaths occurring in this cohort up to November 2000 giving us survival data for between 5 and 7 years after the assessment of SF-36 <xref rid="pone.0016988-Slot1" ref-type="bibr">[18]</xref>.</p></sec><sec id="s2d"><title>Statistical analysis of factors at randomisation associated with fatigue on follow-up</title><p>We analysed fatigue severity (SF-36 vitality) as a continuous variable. We performed multiple linear regression analyses to determine the relationship between fatigue and the following variables measured at randomisation: age, gender, pathological subtype of stroke (ischaemic, haemorrhagic or indeterminate), stroke subtype (total anterior circulation syndrome (TACS), partial anterior circulation syndrome (PACS), lacunar syndrome (LACS), posterior circulation syndrome (POCS) or &#x02018;other&#x02019;), presence of a visible infarct on brain imaging, cardiac rhythm (atrial fibrillation or sinus rhythm) and systolic blood pressure (&#x0003c;140, 140-159, 160-79, &#x0003e;180mmHg.</p><p>Results were reported in the form of regression equations. For a simple linear regression, with one predictor variable, the equation would be of the form <italic>Y&#x0200a;=&#x0200a;a&#x0002b;b&#x0002a;X</italic> i.e. the <italic>Y</italic> variable can be expressed in terms of a constant (<italic>a</italic>) and a slope (<italic>b</italic>) multiplied by the <italic>X</italic> variable. For multiple linear regression analysis when there is more than one independent variable (as in this study), the regression line cannot be visualized in the two dimensional space, but can be computed using a linear equation containing all those variables. Multiple regression procedures estimate a linear equation of the form: Y&#x0200a;=&#x0200a;a&#x0002b;b<sub>1</sub>&#x0002a;X<sub>1</sub>&#x0002b;b<sub>2</sub>&#x0002a;X<sub>2</sub>&#x0002b;&#x02026;&#x0002b;b<sub>p</sub>&#x0002a;X<sub>p</sub>.</p><p>We performed four sensitivity analyses to determine the robustness of the estimates to different assumptions about missing data, in which we: i) removed those with missing vitality data ii) imputed the minimum value recorded iii) imputed the maximum value recorded iv) imputed the mean value observed.</p></sec><sec id="s2e"><title>Statistical analysis of association between mood and fatigue</title><p>At follow-up, patients completed the emotional role score and the mental health scores of the SF-36. The responses were used to calculate a total score for each domain <xref rid="pone.0016988-Ware1" ref-type="bibr">[13]</xref>, ranging from 0-100, with higher score indicating better health.</p><p>We produced multiple regression models which included the variables at randomisation shown to have an effect on vitality score (i.e. the final models generated in the previous section) and the SF-36 mental health and SF-36 emotional role scores. Missing scores for emotional role function and mental health were treated in the same way as missing scores for vitality.</p></sec><sec id="s2f"><title>Statistical analysis of the influence of fatigue at follow-up on subsequent survival</title><p>We generated a Cox proportional hazards model containing the following variables: age, sex, pathological subtype, stroke subtype, visible infarct, atrial fibrillation (at randomisation), systolic blood pressure (at randomisation) and all component parts of the SF-36 at follow-up (vitality, role-emotional, mental health, physical function, bodily pain, general health and social function) with the exception of role-physical. We did not include role-physical as this measures similar constructs to physical function and there were more missing values for role physical than for physical function. For these analyses, survival was measured from the date on which SF-36 vitality was measured.</p><p>Where the initial model generated contained variables which did not reach statistical significance at the 5&#x00025; level, we removed the least significant variable and generated a new model. We repeated this process until the only variables remaining in the model were those which reached statistical significance. We calculated four different models to explore robustness to differing assumptions about missing variables.</p><p>Using the threshold value of at least &#x02018;10 patients per variable&#x02019; rule for the analyses of regression, we had sufficient power for our analyses <xref rid="pone.0016988-Peduzzi1" ref-type="bibr">[19]</xref>.</p></sec></sec><sec id="s3"><title>Results</title><p>The mean age of the participants was 71.1 (SD 10.8) years and 602 (55.7&#x00025;) were men. Other demographic details are shown in <xref ref-type="table" rid="pone-0016988-t001">table 1</xref>. Median SF-36 vitality score (interquartile range) was 37.5 (20.0, 55) for the entire group, 40 (IQR 25, 55) for men and 35 (20,50) for women. The distribution of the vitality scores for men and women is shown in <xref ref-type="fig" rid="pone-0016988-g001">figure 1</xref>.</p><fig id="pone-0016988-g001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0016988.g001</object-id><label>Figure 1</label><caption><title>Distribution of SF-36 vitality scores, according to gender.</title><p>Higher vitality scores indicate less fatigue.</p></caption><graphic xlink:href="pone.0016988.g001"/></fig><table-wrap id="pone-0016988-t001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0016988.t001</object-id><label>Table 1</label><caption><title>Baseline characteristics of the 1080 participants.</title></caption><alternatives><graphic id="pone-0016988-t001-1" xlink:href="pone.0016988.t001"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Characteristic</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Number</td><td align="left" rowspan="1" colspan="1">&#x00025;</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Sex</td><td align="left" rowspan="1" colspan="1">Male</td><td align="left" rowspan="1" colspan="1">602</td><td align="left" rowspan="1" colspan="1">55.7</td></tr><tr><td align="left" rowspan="1" colspan="1">Stroke type</td><td align="left" rowspan="1" colspan="1">Ischaemic</td><td align="left" rowspan="1" colspan="1">918</td><td align="left" rowspan="1" colspan="1">85.0</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Haemorrhagic</td><td align="left" rowspan="1" colspan="1">82</td><td align="left" rowspan="1" colspan="1">7.6</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Indeterminate</td><td align="left" rowspan="1" colspan="1">53</td><td align="left" rowspan="1" colspan="1">4.9</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Not stroke</td><td align="left" rowspan="1" colspan="1">27</td><td align="left" rowspan="1" colspan="1">2.5</td></tr><tr><td align="left" rowspan="1" colspan="1">Stroke sub-type</td><td align="left" rowspan="1" colspan="1">LACS</td><td align="left" rowspan="1" colspan="1">285</td><td align="left" rowspan="1" colspan="1">26.4</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">PACS</td><td align="left" rowspan="1" colspan="1">446</td><td align="left" rowspan="1" colspan="1">41.3</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">POCS</td><td align="left" rowspan="1" colspan="1">124</td><td align="left" rowspan="1" colspan="1">11.5</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">TACS</td><td align="left" rowspan="1" colspan="1">222</td><td align="left" rowspan="1" colspan="1">20.6</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Other</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">0.28</td></tr><tr><td align="left" rowspan="1" colspan="1">Infarct visible</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">265</td><td align="left" rowspan="1" colspan="1">24.5</td></tr><tr><td align="left" rowspan="1" colspan="1">Atrial fibrillation</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">166</td><td align="left" rowspan="1" colspan="1">15.4</td></tr><tr><td align="left" rowspan="1" colspan="1">Systolic blood pressure</td><td align="left" rowspan="1" colspan="1">&#x0003c;140</td><td align="left" rowspan="1" colspan="1">200</td><td align="left" rowspan="1" colspan="1">18.5</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">140 - 159</td><td align="left" rowspan="1" colspan="1">306</td><td align="left" rowspan="1" colspan="1">28.3</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">160 - 179</td><td align="left" rowspan="1" colspan="1">273</td><td align="left" rowspan="1" colspan="1">25.3</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">&#x0003e;&#x0200a;=&#x0200a;179</td><td align="left" rowspan="1" colspan="1">301</td><td align="left" rowspan="1" colspan="1">27.9</td></tr></tbody></table></alternatives></table-wrap><sec id="s3a"><title>Baseline predictors of fatigue</title><p>We analysed SF-36 data from 1080 patients, of whom 1006 (93&#x00025;) had a vitality score recorded. The amount of variability in the vitality score explained by the variables we included was very small [adjusted R<sup>2</sup> values for the 4 models were: 0.037, 0.054, 0.004, 0.034 respectively].</p><p>Three of the four final multiple regression models contained the same variables although the parameter estimates varied slightly. However, when the missing values were set to the maximum recorded value, the model was very different, with only gender predicting fatigue. These equations allow us to estimate SF-36 vitality score if we have data for age, gender, pathological type (ischaemic, haemorrhagic or indeterminate), and subtype (TACS, PACS, LACS, POCS or &#x02018;other&#x02019; stroke subtype).</p><p>Each of models is specified in full below, according to how missing data were dealt with:</p><list list-type="alpha-lower"><list-item><p>Missing values excluded</p><p>
<disp-formula><graphic xlink:href="pone.0016988.e001.jpg" mimetype="image" position="float"/></disp-formula>
</p></list-item><list-item><p>Missing values set to minimum</p><p>
<disp-formula><graphic xlink:href="pone.0016988.e002.jpg" mimetype="image" position="float"/></disp-formula>
</p></list-item><list-item><p>Missing values set to maximum</p><p>
<disp-formula><graphic xlink:href="pone.0016988.e003.jpg" mimetype="image" position="float"/></disp-formula>
</p></list-item><list-item><p>Missing values imputed at mean</p><p>
<disp-formula><graphic xlink:href="pone.0016988.e004.jpg" mimetype="image" position="float"/></disp-formula>
</p></list-item></list><p>Note: &#x02018;Other&#x02019; stroke syndrome is defined as those individuals whose clinical syndromes could not be assigned to one of the four OCSP syndromes.</p></sec><sec id="s3b"><title>Association between mood and fatigue</title><p>We determined association between mood and fatigue, using SF-36 mental health scores, SF-36 emotional role scores and vitality scores. There were missing data from 6.7&#x00025; of mental health scores and 18.3&#x00025; of emotional role scores. <xref ref-type="fig" rid="pone-0016988-g002">Figure 2</xref> shows the univariate relationship between SF-36 mental health and vitality (Pearson correlation coefficient 0.20, p&#x0003c;0.001, n&#x0200a;=&#x0200a;1004). <xref ref-type="fig" rid="pone-0016988-g003">Figure 3</xref> shows the univariate relationship between SF-36 role emotional and vitality (Pearson correlation coefficient 0.38, p&#x0003c;0.001, n&#x0200a;=&#x0200a;863).</p><fig id="pone-0016988-g002" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0016988.g002</object-id><label>Figure 2</label><caption><title>Relationship between SF-36 mental health and vitality.</title><p>Higher scores indicate better health status. As the number of data points are limited, a small random component (&#x02018;jitter&#x02019;) has been added to each variable to better demonstrate the number of patients at a single co-ordinate. (Pearson correlation coefficient 0.20, p&#x0003c;0.001, n&#x0200a;=&#x0200a;1004).</p></caption><graphic xlink:href="pone.0016988.g002"/></fig><fig id="pone-0016988-g003" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0016988.g003</object-id><label>Figure 3</label><caption><title>Relationship between SF-36 role emotional and vitality.</title><p>Higher scores indicate better health status. As the number of data points are limited, a small random component (&#x02018;jitter&#x02019;) has been added to each variable to better demonstrate the number of patients at a single co-ordinate. (Pearson correlation coefficient 0.38, p&#x0003c;0.001, n&#x0200a;=&#x0200a;863).</p></caption><graphic xlink:href="pone.0016988.g003"/></fig><p>For the multiple logistical regression models, gender, age, mental health score and emotional role function were significant predictors of vitality in all four models. The amount of variability in the vitality score explained by variation in the models is small [adjusted R<sup>2</sup> for the 4 models are: 0.18, 0.29, 0.27, 0.16 respectively]. However, these models explain much more of the variance than those models which did not include mental health and emotional role scores.</p><p>The regression equations for all 4 models are shown below.</p><list list-type="alpha-lower"><list-item><p>Missing values excluded</p><p>
<disp-formula><graphic xlink:href="pone.0016988.e005.jpg" mimetype="image" position="float"/></disp-formula>
</p></list-item><list-item><p>Missing values set to minimum</p><p>
<disp-formula><graphic xlink:href="pone.0016988.e006.jpg" mimetype="image" position="float"/></disp-formula>
</p></list-item><list-item><p>Missing values set to maximum</p><p>
<disp-formula><graphic xlink:href="pone.0016988.e007.jpg" mimetype="image" position="float"/></disp-formula>
</p></list-item><list-item><p>Missing values imputed at mean</p><p>
<disp-formula><graphic xlink:href="pone.0016988.e008.jpg" mimetype="image" position="float"/></disp-formula>(&#x02018;&#x0002a;&#x02019; means multiply)</p></list-item></list></sec><sec id="s3c"><title>Influence of fatigue on subsequent survival</title><p>Survival data to November 2000 were available for 1072/1080 (99.3&#x00025;) participants, of whom 420/1072 (39.2&#x00025;) had died. The median number of days' follow-up from randomisation to November 2000 was 5.9 years (IQR 3.8 to 6.6). The median length of follow-up from when SF-36 was measured, in the 1016 participants with this information recorded, was 5.2 years (IQR 2.4 to 5.3).</p><p>
<xref ref-type="table" rid="pone-0016988-t002">Table 2</xref> presents multivariate analyses showing independent predictors of survival. Increasing age, atrial fibrillation (at randomisation) and &#x02018;other&#x02019; stroke subtype predicted shorter survival in all four models. In two models, higher SF-36 vitality at follow-up predicted longer subsequent survival.</p><table-wrap id="pone-0016988-t002" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0016988.t002</object-id><label>Table 2</label><caption><title>Multivariate analyses showing independent predictors of survival, according to the method of dealing with missing SF-36 data.</title></caption><alternatives><graphic id="pone-0016988-t002-2" xlink:href="pone.0016988.t002"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Parameter</td><td align="left" rowspan="1" colspan="1">Hazard ratio</td><td align="left" rowspan="1" colspan="1">Lower 95&#x00025; CI</td><td align="left" rowspan="1" colspan="1">Upper 95&#x00025; CI</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">
<bold>Missing data set to mean</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Age</td><td align="left" rowspan="1" colspan="1">1.060</td><td align="left" rowspan="1" colspan="1">1.048</td><td align="left" rowspan="1" colspan="1">1.072</td></tr><tr><td align="left" rowspan="1" colspan="1">LACS</td><td align="left" rowspan="1" colspan="1">0.78</td><td align="left" rowspan="1" colspan="1">0.585</td><td align="left" rowspan="1" colspan="1">1.039</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02018;Other&#x02019; stroke type</td><td align="left" rowspan="1" colspan="1">4.435</td><td align="left" rowspan="1" colspan="1">1.083</td><td align="left" rowspan="1" colspan="1">18.169</td></tr><tr><td align="left" rowspan="1" colspan="1">PACS</td><td align="left" rowspan="1" colspan="1">0.875</td><td align="left" rowspan="1" colspan="1">0.676</td><td align="left" rowspan="1" colspan="1">1.132</td></tr><tr><td align="left" rowspan="1" colspan="1">POCS</td><td align="left" rowspan="1" colspan="1">0.68</td><td align="left" rowspan="1" colspan="1">0.466</td><td align="left" rowspan="1" colspan="1">0.992</td></tr><tr><td align="left" rowspan="1" colspan="1">Atrial fibrillation (at randomisation)</td><td align="left" rowspan="1" colspan="1">0.708</td><td align="left" rowspan="1" colspan="1">0.555</td><td align="left" rowspan="1" colspan="1">0.904</td></tr><tr><td align="left" rowspan="1" colspan="1">SF-36 vitality</td><td align="left" rowspan="1" colspan="1">0.993</td><td align="left" rowspan="1" colspan="1">0.987</td><td align="left" rowspan="1" colspan="1">0.999</td></tr><tr><td align="left" rowspan="1" colspan="1">SF-36 social role</td><td align="left" rowspan="1" colspan="1">0.996</td><td align="left" rowspan="1" colspan="1">0.992</td><td align="left" rowspan="1" colspan="1">1.000</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Missing data set to maximum</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Age</td><td align="left" rowspan="1" colspan="1">1.061</td><td align="left" rowspan="1" colspan="1">1.049</td><td align="left" rowspan="1" colspan="1">1.073</td></tr><tr><td align="left" rowspan="1" colspan="1">LACS</td><td align="left" rowspan="1" colspan="1">0.778</td><td align="left" rowspan="1" colspan="1">0.584</td><td align="left" rowspan="1" colspan="1">1.036</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02018;Other&#x02019; stroke type</td><td align="left" rowspan="1" colspan="1">4.334</td><td align="left" rowspan="1" colspan="1">1.057</td><td align="left" rowspan="1" colspan="1">17.767</td></tr><tr><td align="left" rowspan="1" colspan="1">PACS</td><td align="left" rowspan="1" colspan="1">0.856</td><td align="left" rowspan="1" colspan="1">0.662</td><td align="left" rowspan="1" colspan="1">1.107</td></tr><tr><td align="left" rowspan="1" colspan="1">POCS</td><td align="left" rowspan="1" colspan="1">0.669</td><td align="left" rowspan="1" colspan="1">0.458</td><td align="left" rowspan="1" colspan="1">0.975</td></tr><tr><td align="left" rowspan="1" colspan="1">Atrial fibrillation (at randomisation)</td><td align="left" rowspan="1" colspan="1">0.694</td><td align="left" rowspan="1" colspan="1">0.544</td><td align="left" rowspan="1" colspan="1">0.885</td></tr><tr><td align="left" rowspan="1" colspan="1">SF-36 social role</td><td align="left" rowspan="1" colspan="1">0.994</td><td align="left" rowspan="1" colspan="1">0.991</td><td align="left" rowspan="1" colspan="1">0.997</td></tr><tr><td align="left" rowspan="1" colspan="1">SF-36 vitality</td><td align="left" rowspan="1" colspan="1">1.001</td><td align="left" rowspan="1" colspan="1">0.996</td><td align="left" rowspan="1" colspan="1">1.005</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Missing data set to minimum</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Age</td><td align="left" rowspan="1" colspan="1">1.058</td><td align="left" rowspan="1" colspan="1">1.046</td><td align="left" rowspan="1" colspan="1">1.070</td></tr><tr><td align="left" rowspan="1" colspan="1">LACS</td><td align="left" rowspan="1" colspan="1">0.784</td><td align="left" rowspan="1" colspan="1">0.589</td><td align="left" rowspan="1" colspan="1">1.044</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02018;Other&#x02019; stroke type</td><td align="left" rowspan="1" colspan="1">4.662</td><td align="left" rowspan="1" colspan="1">1.139</td><td align="left" rowspan="1" colspan="1">19.084</td></tr><tr><td align="left" rowspan="1" colspan="1">PACS</td><td align="left" rowspan="1" colspan="1">0.873</td><td align="left" rowspan="1" colspan="1">0.675</td><td align="left" rowspan="1" colspan="1">1.129</td></tr><tr><td align="left" rowspan="1" colspan="1">POCS</td><td align="left" rowspan="1" colspan="1">0.677</td><td align="left" rowspan="1" colspan="1">0.464</td><td align="left" rowspan="1" colspan="1">0.988</td></tr><tr><td align="left" rowspan="1" colspan="1">Atrial fibrillation (at randomisation)</td><td align="left" rowspan="1" colspan="1">0.710</td><td align="left" rowspan="1" colspan="1">0.556</td><td align="left" rowspan="1" colspan="1">0.905</td></tr><tr><td align="left" rowspan="1" colspan="1">SF-36 vitality</td><td align="left" rowspan="1" colspan="1">0.988</td><td align="left" rowspan="1" colspan="1">0.984</td><td align="left" rowspan="1" colspan="1">0.993</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Missing data excluded</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Age</td><td align="left" rowspan="1" colspan="1">1.065</td><td align="left" rowspan="1" colspan="1">1.052</td><td align="left" rowspan="1" colspan="1">1.078</td></tr><tr><td align="left" rowspan="1" colspan="1">Atrial fibrillation (at randomisation)</td><td align="left" rowspan="1" colspan="1">0.689</td><td align="left" rowspan="1" colspan="1">0.530</td><td align="left" rowspan="1" colspan="1">0.897</td></tr><tr><td align="left" rowspan="1" colspan="1">SF-36 general health</td><td align="left" rowspan="1" colspan="1">0.989</td><td align="left" rowspan="1" colspan="1">0.984</td><td align="left" rowspan="1" colspan="1">0.994</td></tr><tr><td align="left" rowspan="1" colspan="1">SF-36 vitality</td><td align="left" rowspan="1" colspan="1">0.994</td><td align="left" rowspan="1" colspan="1">0.988</td><td align="left" rowspan="1" colspan="1">1.001</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt101"><label/><p>LACS&#x0200a;=&#x0200a;lacunar syndrome, PACS&#x0200a;=&#x0200a;partial anterior circulation syndrome, TACS&#x0200a;=&#x0200a;total anterior circulation syndrome, POCS&#x0200a;=&#x0200a;posterior circulation syndrome</p></fn><fn id="nt102"><label/><p>Note that hazard ratios and 95&#x00025; CI for SF-36 vitality are provided for all four models, even though the hazard ratio reached statistical significance in only two of the models.</p></fn></table-wrap-foot></table-wrap></sec></sec><sec id="s4"><title>Discussion</title><p>To our knowledge, this is the first study to explore not only the factors at stroke onset that predict post-stroke fatigue, but also the relationship between fatigue and mood, and the influence of fatigue at follow-up on subsequent survival. Increasing age, worse emotional role function and worse mental health score measured at follow-up were significantly associated with fatigue. Fatigue on follow-up was associated with significantly reduced subsequent survival in two models. Although we did not specifically aim to compare SF-36 vitality scores after stroke with a general population, we noted that the median SF-36 vitality score of 37.5 was substantially lower than the mean SF-36 vitality score of 55.8 from the general population aged 70-74 years <xref rid="pone.0016988-Walters1" ref-type="bibr">[20]</xref>.</p><p>The study had several strengths: it was a very large, prospective and conducted in a single, well characterised cohort of stroke patients recruited at a uniform time point (stroke onset); it used a valid and reliable measure of fatigue after stroke (SF-36 vitality score) <xref rid="pone.0016988-Lynch1" ref-type="bibr">[11]</xref>, <xref rid="pone.0016988-Mead1" ref-type="bibr">[12]</xref>. It explored baseline predictors of fatigue, relationship between fatigue and mood, and the influence of fatigue on survival in the same large group of patients.</p><p>Increasing age, lower emotional role function and lower mental health score were significantly associated with fatigue in all four models and female sex was also significant in three models. Importantly, the factors we identified accounted for only a small amount of variance in fatigue, suggesting that other factors, for which we did not collect data, must also be associated with fatigue.</p><p>Previous cross-sectional studies have explored the relationship between fatigue and mood disorders after stroke, with most but not all finding associations. Thus, the evidence points to an association between fatigue and mood disorders. However, we cannot determine direction of causality from current evidence i.e. whether fatigue causes mood disorders or whether mood disorders cause fatigue. In the general population, SF-36 vitality scores are lower in women than men, and fall with increasing age <xref rid="pone.0016988-Walters1" ref-type="bibr">[20]</xref>, and fatigue is a well-recognised symptom of mood disorders. Thus, these findings are consistent with findings from the general population.</p><p>The extent to which the post-stroke vitality scores might have been explained by pre-stroke scores is uncertain. One previous study found that 62&#x00025; of patients with post-stroke fatigue had had pre-stroke fatigue <xref rid="pone.0016988-ChoiKwan1" ref-type="bibr">[4]</xref>, suggesting that some fatigue was present <italic>before</italic> the stroke and that some develops <italic>after</italic> the stroke.</p><p>After correction for role emotional and mental health, we found no evidence of a relationship between OCSP stroke subtype, as an indicator of stroke lesion location and size, and fatigue. Ours is the largest study to date to explore associations between fatigue and stroke lesion location and size, and so this is an important negative finding. Two previous studies have suggested that fatigue is more common in brain stem strokes <xref rid="pone.0016988-Naess1" ref-type="bibr">[5]</xref>, <xref rid="pone.0016988-Staub1" ref-type="bibr">[7]</xref>, although other studies did not find an association between brain stem strokes and fatigue. Although fatigue may not be related to lesion location, it is, nevertheless, possible that fatigue may have a &#x02018;central&#x02019; origin i.e. it might be a direct consequence of a cerebral infarct or cerebral haemorrhage <xref rid="pone.0016988-Winward1" ref-type="bibr">[21]</xref>. The observation that fatigue after stroke is unlike anything ever experienced before by stroke survivors <xref rid="pone.0016988-Flinn1" ref-type="bibr">[22]</xref> supports the idea that fatigue might be directly caused by the brain lesion.</p><p>One study has suggested that fatigue may be related to dysregulation of blood pressure after stroke, perhaps as a result of antihypertensive drugs <xref rid="pone.0016988-Harbison1" ref-type="bibr">[10]</xref>. We did not find an association between <italic>baseline</italic> blood pressure and fatigue, but were unable to explore relationship between fatigue and <italic>current</italic> blood pressure.</p><p>Intriguingly, lower SF-36 vitality scores (i.e. more fatigue) in our study were associated with shorter survival. However, after correction for pain, social role functioning, physical function and general health, fatigue remained a significant predictor in only two models. Nonetheless, if confirmed, this would strengthen the case for further studies into the biology of post-stroke fatigue.</p><p>Our study has some weaknesses. Our data were from a randomised trial rather than from a population-based study, although the inclusion criteria for IST were broad. The SF-36 scores were obtained at a median of 64 weeks after stroke onset which perhaps somewhat limits the generalisability of the findings. The 77&#x00025; response rate leads to some degree of uncertainty in the analyses, though it is similar to the previous postal survey of fatigue after stroke <xref rid="pone.0016988-Glader1" ref-type="bibr">[1]</xref>. There were missing data items in some of the SF-36 forms. We could have simplified data analysis by performing only one analysis after excluding those with missing data, but this might have biased our results, because non-responders may have been systematically different from those who did respond e.g. more depressed, more fatigued. There is no consensus about how to deal with missing data in this type of study. Each possible method has its own potential biases, so we dealt with these missing data items in four different ways statistically. Reassuringly, final regression models for SF-36 vitality were similar, and importantly, all explained only a small amount of variance in fatigue. We were unable to correct our analyses for levels of dependence, which is known to influence survival <xref rid="pone.0016988-Slot1" ref-type="bibr">[18]</xref>, but we did correct for SF-36 self-reported physical function. There were a few patients who did not have a definite diagnosis of stroke; we decided to include these as the physician recruiting them to IST felt that they had had a stroke. Although fatigue is a complex experience for patients, in large studies such as this, it is necessary to use a quick, simple tool, such as the SF-36 vitality component, that has been validated against a case definition for clinically significant fatigue after stroke <xref rid="pone.0016988-Lynch1" ref-type="bibr">[11]</xref>, <xref rid="pone.0016988-Mead1" ref-type="bibr">[12]</xref>. Despite these weaknesses, this very large study represents an important new contribution to the sparse literature on fatigue after stroke.</p><p>What are the implications of this study? Physicians should consider mood disorders in patients with post-stroke fatigue. Further research is required to determine the relationship between pre-stroke and post-stroke fatigue, the natural history of fatigue after stroke, the direction of causality between mood disorders and fatigue and to determine whether fatigue is an independent predictor of survival and, if it is, the biological mechanism that accounts for the survival disadvantage that fatigue confers. There is clearly also a need to develop interventions for fatigue after stroke and test them in appropriate trials <xref rid="pone.0016988-McGeough1" ref-type="bibr">[23]</xref>.</p></sec></body><back><fn-group><fn fn-type="COI-statement"><p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p></fn><fn fn-type="financial-disclosure"><p><bold>Funding: </bold>This analysis was funded by Chief Scientist Office Scottish Government CZG/2/387. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.</p></fn></fn-group><ref-list><title>References</title><ref id="pone.0016988-Glader1"><label>1</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Glader</surname><given-names>E-L</given-names></name><name><surname>Stegmayr</surname><given-names>B</given-names></name><name><surname>Asplund</surname><given-names>K</given-names></name></person-group>
<year>2002</year>
<article-title>Post-stroke fatigue. A 2 year follow-up study of stroke patients in Sweden.</article-title>
<source>Stroke</source>
<volume>33</volume>
<fpage>1327</fpage>
<lpage>1333</lpage>
<pub-id pub-id-type="pmid">11988611</pub-id></element-citation></ref><ref id="pone.0016988-Leegard1"><label>2</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Leegard</surname><given-names>OF</given-names></name></person-group>
<year>1983</year>
<article-title>Diffuse cerebral symtoms in convalescents from cerebral infarction and myocardial infarction.</article-title>
<source>Acta Neurol Scand</source>
<volume>67</volume>
<fpage>348</fpage>
<lpage>355</lpage>
<pub-id pub-id-type="pmid">6613521</pub-id></element-citation></ref><ref id="pone.0016988-vander1"><label>3</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>van der</surname><given-names>Werf</given-names></name><name><surname>van den Broek</surname><given-names>HLP</given-names></name><name><surname>Anten</surname><given-names>HWM</given-names></name><name><surname>Bleijenberg</surname><given-names>G</given-names></name></person-group>
<year>2001</year>
<article-title>Experience of Severe Fatigue long after stroke and its relation to depressive symptoms and disease characteristics.</article-title>
<source>Eur Neurol</source>
<volume>45</volume>
<fpage>28</fpage>
<lpage>33</lpage>
<pub-id pub-id-type="pmid">11150837</pub-id></element-citation></ref><ref id="pone.0016988-ChoiKwan1"><label>4</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Choi-Kwan</surname><given-names>S</given-names></name><name><surname>Han</surname><given-names>SW</given-names></name><name><surname>Kwon</surname><given-names>SU</given-names></name><name><surname>Kim</surname><given-names>JS</given-names></name></person-group>
<year>2005</year>
<article-title>Post-stroke fatigue: Characteristics and Related factors.</article-title>
<source>Cerebrovasc Dis</source>
<volume>19</volume>
<fpage>84</fpage>
<lpage>90</lpage>
<pub-id pub-id-type="pmid">15608431</pub-id></element-citation></ref><ref id="pone.0016988-Naess1"><label>5</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Naess</surname><given-names>H</given-names></name><name><surname>Nyland</surname><given-names>HI</given-names></name><name><surname>Thomassen</surname><given-names>L</given-names></name><name><surname>Aarseth</surname><given-names>J</given-names></name><name><surname>Myhr</surname><given-names>K-M</given-names></name></person-group>
<year>2005</year>
<article-title>Fatigue at long-term follow-up in young adults with cerebral infarction.</article-title>
<source>Cerebrovasc Dis</source>
<volume>20</volume>
<fpage>245</fpage>
<lpage>250</lpage>
<pub-id pub-id-type="pmid">16123544</pub-id></element-citation></ref><ref id="pone.0016988-Morley1"><label>6</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Morley</surname><given-names>W</given-names></name><name><surname>Jackson</surname><given-names>K</given-names></name><name><surname>Mead</surname><given-names>G</given-names></name></person-group>
<year>2005</year>
<article-title>Post-Stroke fatigue: an important yet neglected synptom.</article-title>
<source>Age Ageing</source>
<volume>34</volume>
<fpage>313</fpage>
</element-citation></ref><ref id="pone.0016988-Staub1"><label>7</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Staub</surname><given-names>F</given-names></name><name><surname>Bogousslavsky</surname><given-names>J</given-names></name></person-group>
<year>2001</year>
<article-title>Fatigue after stroke: a major but neglected issue.</article-title>
<source>Cerebrovasc Dis</source>
<volume>12</volume>
<fpage>75</fpage>
<lpage>81</lpage>
<pub-id pub-id-type="pmid">11490100</pub-id></element-citation></ref><ref id="pone.0016988-Ingles1"><label>8</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ingles</surname><given-names>JL</given-names></name><name><surname>Eskes</surname><given-names>GA</given-names></name><name><surname>Phillips</surname><given-names>SJ</given-names></name></person-group>
<year>1999</year>
<article-title>Fatigue after stroke.</article-title>
<source>Arch Phys Med Rehabil</source>
<volume>80</volume>
<fpage>173</fpage>
<lpage>178</lpage>
<pub-id pub-id-type="pmid">10025492</pub-id></element-citation></ref><ref id="pone.0016988-Schepers1"><label>9</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Schepers</surname><given-names>VP</given-names></name><name><surname>Wisser-Meily</surname><given-names>AM</given-names></name><name><surname>Ketelaar</surname><given-names>A</given-names></name><name><surname>Lindeman</surname><given-names>E</given-names></name></person-group>
<year>2006</year>
<article-title>Post-stroke fatigue: course and its relationship to personal and stroke-related factors.</article-title>
<source>Arch Phys Med Rehabil</source>
<volume>87</volume>
<fpage>184</fpage>
<lpage>8</lpage>
<pub-id pub-id-type="pmid">16442970</pub-id></element-citation></ref><ref id="pone.0016988-Harbison1"><label>10</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Harbison</surname><given-names>JA</given-names></name><name><surname>Walsh</surname><given-names>S</given-names></name><name><surname>Kenny</surname><given-names>RA</given-names></name></person-group>
<year>2009</year>
<article-title>Hypertension and daytime hypotension on ambulatory blood pressure is associated with fatigue following stroke and TIA.</article-title>
<source>Q J Med</source>
<volume>102</volume>
<fpage>109</fpage>
<lpage>115</lpage>
</element-citation></ref><ref id="pone.0016988-Lynch1"><label>11</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lynch</surname><given-names>J</given-names></name><name><surname>Mead</surname><given-names>GE</given-names></name><name><surname>Greig</surname><given-names>CA</given-names></name><name><surname>Young</surname><given-names>A</given-names></name><name><surname>Lewis S et</surname><given-names>al</given-names></name></person-group>
<year>2007</year>
<article-title>Development and evaluation of a case definition for fatigue after stroke.</article-title>
<source>J Psychosom Res</source>
<volume>63</volume>
<fpage>539</fpage>
<lpage>544</lpage>
<pub-id pub-id-type="pmid">17980228</pub-id></element-citation></ref><ref id="pone.0016988-Mead1"><label>12</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mead</surname><given-names>GE</given-names></name><name><surname>Lynch</surname><given-names>J</given-names></name><name><surname>Greig</surname><given-names>CA</given-names></name><name><surname>Young</surname><given-names>A</given-names></name><name><surname>Lewis S et</surname><given-names>al</given-names></name></person-group>
<year>2007</year>
<article-title>Evaluation of fatigue scales in stroke patients.</article-title>
<source>Stroke</source>
<volume>38</volume>
<fpage>2090</fpage>
<lpage>5</lpage>
<pub-id pub-id-type="pmid">17525397</pub-id></element-citation></ref><ref id="pone.0016988-Ware1"><label>13</label><element-citation publication-type="other">
<person-group person-group-type="author"><name><surname>Ware</surname><given-names>JE</given-names></name><name><surname>Snow</surname><given-names>KK</given-names></name><name><surname>Kosinski</surname><given-names>M</given-names></name><name><surname>Gandek</surname><given-names>B</given-names></name></person-group>
<year>1993</year>
<article-title>SF-36 Health Survey: Manual and Interpretation Guide.</article-title>
<comment>Boston Mass: Health Institute, New England Medical Centre</comment>
</element-citation></ref><ref id="pone.0016988-Dorman1"><label>14</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dorman</surname><given-names>PJ</given-names></name><name><surname>Slattery</surname><given-names>J</given-names></name><name><surname>Farrell</surname><given-names>B</given-names></name><name><surname>Dennis</surname><given-names>MS</given-names></name><name><surname>Sandercock</surname><given-names>PAG</given-names></name></person-group>
<collab>the United Kingdom Collaborators in the International Stroke Trial</collab>
<year>1997</year>
<article-title>A randomised comparison of the Euroquol and Short Form-36 after stroke.</article-title>
<source>BMJ</source>
<volume>315</volume>
<fpage>461</fpage>
<pub-id pub-id-type="pmid">9284664</pub-id></element-citation></ref><ref id="pone.0016988-Dorman2"><label>15</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dorman</surname><given-names>PJ</given-names></name><name><surname>Dennis</surname><given-names>MS</given-names></name></person-group>
<collab>Sandercock PAG for the United Kingdom Collaborators in the International Stroke Trial</collab>
<year>1999</year>
<article-title>How do scores on the Euroquol Relate to Scores on the SF-36 after stroke?</article-title>
<source>Stroke</source>
<volume>30</volume>
<fpage>2146</fpage>
<lpage>2151</lpage>
<pub-id pub-id-type="pmid">10512920</pub-id></element-citation></ref><ref id="pone.0016988-Dorman3"><label>16</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dorman</surname><given-names>PJ</given-names></name><name><surname>Slattery</surname><given-names>J</given-names></name><name><surname>Farrell</surname><given-names>B</given-names></name><name><surname>Dennis</surname><given-names>MS</given-names></name><name><surname>Sandercock</surname><given-names>P</given-names></name></person-group>
<year>1998</year>
<article-title>Qualitative comparison of the reliability of Health Status assessments with the Euroquol and SF-36 questionnaires after stroke.</article-title>
<source>Stroke</source>
<volume>29</volume>
<fpage>63</fpage>
<lpage>68</lpage>
<pub-id pub-id-type="pmid">9445330</pub-id></element-citation></ref><ref id="pone.0016988-Anonymous1"><label>17</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Anonymous</surname></name></person-group>
<year>1997</year>
<article-title>The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. International Stroke Trial Collaborative Group.</article-title>
<source>Lancet</source>
<volume>349</volume>
<fpage>1569</fpage>
<lpage>81</lpage>
<pub-id pub-id-type="pmid">9174558</pub-id></element-citation></ref><ref id="pone.0016988-Slot1"><label>18</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bruins</surname><given-names>SK</given-names></name><name><surname>Berge</surname><given-names>E</given-names></name><name><surname>Dorman</surname><given-names>P</given-names></name><name><surname>Lewis</surname><given-names>S</given-names></name><name><surname>Dennis</surname><given-names>M</given-names></name><etal/></person-group>
<collab>Oxfordshire Community Stroke Project, the International Stroke Trial (UK); Lothian Stroke Register</collab>
<year>2008</year>
<article-title>Impact of functional outcome at six months on long term survival in patients with ischaemic stroke: prospective cohort studies.</article-title>
<source>BMJ</source>
<volume>336</volume>
<fpage>376</fpage>
<lpage>379</lpage>
<pub-id pub-id-type="pmid">18230644</pub-id></element-citation></ref><ref id="pone.0016988-Peduzzi1"><label>19</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Peduzzi</surname><given-names>P</given-names></name><name><surname>Concato</surname><given-names>J</given-names></name><name><surname>Kemper</surname><given-names>E</given-names></name><name><surname>Holford</surname><given-names>TR</given-names></name><name><surname>Feinstein</surname><given-names>AR</given-names></name></person-group>
<year>1996</year>
<article-title>A simulation study of the number of events per variable in logistic regression analysis.</article-title>
<source>J Clin Epidemiol</source>
<volume>49</volume>
<fpage>1373</fpage>
<lpage>1379</lpage>
<pub-id pub-id-type="pmid">8970487</pub-id></element-citation></ref><ref id="pone.0016988-Walters1"><label>20</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Walters</surname><given-names>SJ</given-names></name><name><surname>Munro</surname><given-names>JF</given-names></name><name><surname>Brazier</surname><given-names>JE</given-names></name></person-group>
<year>2001</year>
<article-title>Using the SF-36 with older adults: a cross-sectional community based survey.</article-title>
<source>Age and Ageing</source>
<volume>30</volume>
<fpage>337</fpage>
<lpage>343</lpage>
<pub-id pub-id-type="pmid">11509313</pub-id></element-citation></ref><ref id="pone.0016988-Winward1"><label>21</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Winward</surname><given-names>C</given-names></name><name><surname>Sackley</surname><given-names>C</given-names></name><name><surname>Metha</surname><given-names>S</given-names></name><name><surname>Rothwell</surname><given-names>PM</given-names></name></person-group>
<year>2009</year>
<article-title>A Population-Based Study of the Prevalence of Fatigue After Transient Ischemic Attack and Minor Stroke.</article-title>
<source>Stroke</source>
<volume>40</volume>
<fpage>757</fpage>
<lpage>761</lpage>
<pub-id pub-id-type="pmid">19131658</pub-id></element-citation></ref><ref id="pone.0016988-Flinn1"><label>22</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Flinn</surname><given-names>NA</given-names></name><name><surname>Stube</surname><given-names>JE</given-names></name></person-group>
<year>2009</year>
<article-title>Post-stroke fatigue: qualitative study of three focus groups.</article-title>
<source>Occup Ther Int</source>
<volume>17</volume>
<fpage>81</fpage>
<lpage>91</lpage>
</element-citation></ref><ref id="pone.0016988-McGeough1"><label>23</label><element-citation publication-type="other">
<person-group person-group-type="author"><name><surname>McGeough</surname><given-names>E</given-names></name><name><surname>Pollock</surname><given-names>A</given-names></name><name><surname>Smith</surname><given-names>LN</given-names></name><name><surname>Dennis</surname><given-names>M</given-names></name><name><surname>Sharpe</surname><given-names>M</given-names></name><etal/></person-group>
<year>2009</year>
<article-title>Interventions for post-stroke fatigue.</article-title>
<comment>Cochrane Database of Systematic Reviews, Issue 3. Art. No.:CD007030.DOI: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/14651858.CD007030.pub2">10.1002/14651858.CD007030.pub2</ext-link></comment>
</element-citation></ref></ref-list></back></article>